WO2014083612A1 - 腹膜透析液 - Google Patents
腹膜透析液 Download PDFInfo
- Publication number
- WO2014083612A1 WO2014083612A1 PCT/JP2012/080625 JP2012080625W WO2014083612A1 WO 2014083612 A1 WO2014083612 A1 WO 2014083612A1 JP 2012080625 W JP2012080625 W JP 2012080625W WO 2014083612 A1 WO2014083612 A1 WO 2014083612A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peritoneal dialysis
- liquid
- icodextrin
- solution
- dialysis solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/202—Separating means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2093—Containers having several compartments for products to be mixed
Definitions
- the present invention relates to a peritoneal dialysis solution containing icodextrin.
- Peritoneal dialysis which is one of the symptomatic treatments for renal failure, is one of the home medical treatments because it requires less equipment and instruments and less time constraints than dialysis performed by artificial kidneys.
- Many peritoneal dialysates currently in use use glucose as an osmotic substance.
- Glucose has the advantage of being relatively safe and inexpensive, but because of its low molecular weight, it is rapidly absorbed from the peritoneum and cannot provide a continuous water removal effect. From the above situation, a search for an osmotic substance instead of glucose capable of maintaining ultrafiltration during long-time storage has been conducted, and it has been found that icodextrin, a glucose polymer, is suitable for peritoneal dialysis fluid.
- Icodextrin has a large molecular weight, so it is not absorbed rapidly through the peritoneum, but acts mainly as a colloid osmotic substance, and can obtain a water removal effect while maintaining the osmotic pressure with plasma. .
- peritoneal dialysis fluids that use icodextrin are formulated so that the drug solution is in the range of pH 5.0 to 5.5 in order to prevent decomposition and coloring of icodextrin.
- the pH of the peritoneal dialysis fluid has a great influence on the stability of icodextrin. If the pH is increased as it is, the icodextrin is decomposed into glucose during production and storage, and the peritoneal dialysis fluid is degraded due to the deterioration of the glucose. Coloring will result in a significant reduction in product value. That is, the absorbance at 284 nm, which is an indicator of 5-hydroxymethylfurfural, which is the main degradation product of glucose, increases over time.
- Patent Document 1 A formulation has been developed (Patent Document 1).
- the present invention provides a peritoneal dialysis solution that maximizes the stability of icodextrin during heat sterilization and subsequent storage, and has a pH close to a physiological range.
- the present invention provides an acidic first solution containing 60.0 to 94.0 g / L icodextrin and 0 to 2.34 g / L sodium chloride, and an alkaline first solution containing an alkaline pH adjuster.
- a sterilized peritoneal dialysis solution comprising two liquids, wherein the pH of the first liquid after sterilization is 5.0 to 5.5, and the pH of the second liquid after sterilization is 6.5 to 7.5.
- This is a peritoneal dialysis solution having a pH of 6.0 to 7.5 after mixing the first solution and the second solution after sterilization.
- the present invention is the peritoneal dialysis solution according to the above (1), wherein the first solution contains neither lactic acid nor lactate.
- the lactate include sodium lactate, potassium lactate, and calcium lactate.
- the present invention is the peritoneal dialysis solution according to the above (1) or (2), wherein the alkaline pH adjuster of the second solution contains at least one of sodium hydroxide and sodium bicarbonate.
- the present invention is the peritoneal dialysis solution according to any one of (1) to (4), which is housed in a medical bag body, wherein the bag body is provided by a partitioning means capable of opening the inside thereof.
- the second fluid is a peritoneal dialysis fluid stored in the second chamber.
- the peritoneal dialysis fluid of the present invention is obtained by separating peritoneal dialysis fluid over time with a peritoneal dialysis fluid that separates and stores components of peritoneal dialysis fluid containing icodextrin and alkaline peritoneal dialysis fluid, particularly lactic acid and lactate.
- the increase in absorbance at 284 nm can be suppressed, that is, the glucose degradation product of icodextrin during heat sterilization and subsequent storage can be significantly suppressed, and a peritoneal dialysis solution having excellent stability can be provided.
- the peritoneal dialysis solution of the present invention is composed of a first liquid mainly containing icodextrin and a second liquid containing no icodextrin and containing an alkaline pH adjuster, and the first liquid and the second liquid are mixed immediately before use.
- This is a two-part peritoneal dialysis solution, which has a pH of 6.0 to 7.5 after mixing.
- the content of icodextrin in the first liquid is 60.0 to 94.0 g / L, preferably 65.0 to 85.0 g / L.
- the content of icodextrin is less than 60.0 g / L, the osmotic pressure after mixing the first liquid and the second liquid is too low and sufficient dialysis cannot be expected, and the icodextrin contained in the first liquid
- the content of dextrin exceeds 94.0 g / L, the content of glucose degradation products increases, which is not preferable. That is, as a result, the decomposition of icodextrin into glucose during heat sterilization and subsequent storage can be suitably suppressed, and a peritoneal dialysis solution that is stable and excellent in storage stability can be realized.
- the content of sodium chloride in the first liquid is 0 to 2.34 g / L, preferably 1.78 to 2.15 g / L.
- Sodium chloride is blended for the purpose of adjusting the osmotic pressure, and when the content of sodium chloride in the first liquid exceeds 2.34 g / L, the amount of glucose degradation products increases, which is not preferable.
- the pH of the first liquid after sterilization is in the acidic range, specifically, the range of pH 4.7 to 5.5 is preferable, and the range of pH 5.0 to 5.5 is more preferable. If the pH is less than 4.7 or exceeds pH 5.5, the amount of glucose degradation product increases, which is not preferable.
- the pH may be adjusted using, for example, hydrochloric acid or lactic acid.
- the second liquid contains at least one of sodium hydroxide and sodium bicarbonate as an alkaline pH adjuster.
- the content of the alkaline pH adjuster is such that at least one of lactate or lactic acid blended as an alkalinizing agent is added, and the sterilized first and second liquids are mixed to adjust the pH of the retroperitoneal dialysate to pH 6.0 -7.5, preferably the amount necessary to adjust the pH to 6.5-7.5.
- the pH after mixing is less than 6.0, the immune defense mechanism of macrophages is reduced and the peritoneal mesothelial cells are highly impaired. Concerned.
- At least one of lactate or lactic acid blended as an alkalizing agent is contained, and the content thereof is not particularly limited, as long as the lactate ion contains the same amount as a normal peritoneal dialysis solution. It is preferably 30 to 45 mEq / L as a lactate ion after mixing.
- the alkalinizing agent may be contained in either the first liquid or the second liquid, but it is icodextrin in terms of stability of peritoneal dialysis solution such as inhibition of decomposition of icodextrin into glucose and inhibition of the decomposition of glucose. It is preferable to mix
- the lactate include sodium lactate, potassium lactate, and calcium lactate, and preferably sodium lactate.
- the peritoneal dialysis solution of the present invention contains various components contained in a normal peritoneal dialysis solution, that is, sodium ions, calcium ions, magnesium ions, chlorine ions, and the like. These contents may be the same as the normal peritoneal dialysis solution.
- sodium ions are 100 to 200 mEq / L
- calcium ions are 0 to 5 mEq / L
- magnesium ions are It is preferably 0 to 5 mEq / L and the chlorine ion is preferably 50 to 180 mEq / L.
- These components may be contained in either the first liquid or the second liquid, but are preferably blended into the second liquid not containing icodextrin from the viewpoint of the stability of the peritoneal dialysis liquid.
- These components may be blended in the peritoneal dialysis solution of the present invention as lactic acid, sodium lactate, sodium chloride, calcium chloride, magnesium chloride, etc. in the same manner as a normal peritoneal dialysis solution.
- the first solution and the second solution are separately filled and packaged in a container made of polypropylene or polyvinyl chloride, sterilized, and immediately before use, the first solution and the second solution The solution is mixed aseptically.
- the peritoneal dialysis solution of the present invention is a medical bag body, and has a first chamber and a second chamber formed by being separated by a partitioning means capable of opening the inside thereof. It is preferable that the first liquid and the second liquid are separated and accommodated in one having a discharge port that communicates the inside and outside of the medical bag body. At this time, it is preferable to store the first liquid in the first chamber and the second liquid in the second chamber. Thereby, even if the first liquid and the second liquid are administered without mixing, administration of the first liquid that is relatively safe in terms of osmotic pressure can be administered.
- the partitioning means that can be opened, there is a heat seal that can be broken by the hydraulic pressure of the first liquid or the second liquid stored when one of the first chamber or the second chamber is pressed. Thereby, mixing with a 1st liquid and a 2nd liquid can be performed easily.
- a medical bag specifically, a container of Midperic (registered trademark) (manufactured by Terumo Corporation) can be mentioned.
- examples of the sterilization method include autoclave sterilization (high pressure steam sterilization), and the conditions are preferably 110 to 140 ° C. for 5 to 50 minutes, and specifically 121 ° C. for 30 minutes.
- Example 1 75 g of icodextrin was dissolved in 840 mL of water for injection to prepare a first solution. Dissolve 5.35 g sodium chloride, 4.48 g sodium lactate, 0.257 g calcium chloride, and 0.051 g magnesium chloride hexahydrate in 160 mL of water for injection and adjust the pH with sodium hydroxide.
- the second liquid was prepared. First, 840 mL of the first liquid and 160 mL of the second liquid were filled in a polypropylene multi-chamber container (a container of Midperic (registered trademark) (manufactured by Terumo Corporation)), and then placed in a three-sided bag made of polypropylene / nylon / polypropylene. I wrapped it.
- a polypropylene multi-chamber container a container of Midperic (registered trademark) (manufactured by Terumo Corporation)
- Example 2 First solution was prepared by dissolving 75 g of icodextrin and 1.87 g of sodium chloride in 840 mL of water for injection. Also, 3.48 g of sodium chloride, 4.48 g of sodium lactate, 0.257 g of calcium chloride, and 0.051 g of magnesium chloride hexahydrate are dissolved in 160 mL of water for injection and the pH is adjusted with sodium hydroxide.
- the second liquid was prepared. After filling and heat-sterilizing 840 mL of the first liquid and 160 mL of the second liquid under the same conditions as in Example 1, the pH of the first liquid, the second liquid, and the mixed liquid (peritoneal dialysis liquid) was measured. The pH of the first liquid was 5.1, the pH of the second liquid was 7.0, and the pH of the mixed liquid was 6.6.
- the peritoneal dialysis solution of the present invention can be peritoneal dialysis of less than 0.15 at an absorbance of 284 nm after heat sterilization or after lapse of 7 days at 60 ° C. by performing appropriate heat sterilization. Liquid can be realized. This is something that could not have been predicted from the prior art.
- the peritoneal dialysis solution of the present invention can control the pH to a physiological range, suppress the decomposition of icodextrin during heat sterilization and subsequent storage to the maximum, and is extremely stable. It can be used industrially as an excellent peritoneal dialysis solution.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
また、本発明において、第2液は、アルカリ性pH調整剤として、水酸化ナトリウムおよび炭酸水素ナトリウムの少なくとも一つを含むものである。アルカリ性pH調整剤の含有量は、アルカリ化剤として配合される乳酸塩または乳酸の少なくとも一つを加え、滅菌後の第1液及び第2液を混合した後腹膜透析液のpHをpH6.0~7.5、好ましくは、pH6.5~7.5に調整するために必要な量である。
75gのイコデキストリンを840mLの注射用水に溶解し、第1液を調製した。また、5.35gの塩化ナトリウム、4.48gの乳酸ナトリウム、0.257gの塩化カルシウム、および0.051gの塩化マグネシウム・六水塩を160mLの注射用水に溶解し、水酸化ナトリウムでpHを調整し、第2液を調製した。第1液840mL、第2液160mLを、それぞれポリプロピレン製複室容器(ミッドペリック(登録商標)(テルモ株式会社製)の容器)に充填した後、ポリプロピレン/ナイロン/ポリプロピレン製の三方袋に入れて脱気包装した。その後、オートクレーブを用いて加熱滅菌(121℃、30分)を行った後、第1液、第2液、および混合液(腹膜透析液)のpHを測定した。第1液のpHは5.1、第2液のpHは7.0、混合液のpHは6.6であった。
75gのイコデキストリンおよび1.87gの塩化ナトリウムを840mLの注射用水に溶解し、第1液を調製した。また、3.48gの塩化ナトリウム、4.48gの乳酸ナトリウム、0.257gの塩化カルシウム、および0.051gの塩化マグネシウム・六水塩を160mLの注射用水に溶解し、水酸化ナトリウムでpHを調整し、第2液を調製した。第1液840mL、第2液160mLを、実施例1と同様の条件で、充填、加熱滅菌した後、第1液、第2液および混合液(腹膜透析液)のpHを測定した。第1液のpHは5.1、第2液のpHは7.0、混合液のpHは6.6であった。
75gのイコデキストリンおよび4.48gの乳酸ナトリウムを840mLの注射用水に溶解し、第1液を調製した。また、5.35gの塩化ナトリウム、0.257gの塩化カルシウム・二水塩、および0.051gの塩化マグネシウム・六水塩を160mLの注射用水に溶解し、水酸化ナトリウムでpHを調整し、第2液を調製した。第1液840mL、第2液160mLを、実施例1と同様の条件で、充填、加熱滅菌した後、第1液、第2液および混合液(腹膜透析液)のpHを測定した。第1液のpHは5.4、第2液のpHは6.9、混合液のpHは6.6であった。
75gのイコデキストリン、5.35gの塩化ナトリウム、18.3gの塩化カルシウム・二水塩、および5.08gの塩化マグネシウム・六水塩を840m、4.48gの乳酸ナトリウムを1000mLの注射用水に溶解し、調製した。調製液1000mLをポリプロピレン製単室容器に充填した後、ポリプロピレン/ナイロン/ポリプロピレン製の三方袋に入れて脱気包装した。その後、オートクレーブを用いて加熱滅菌(121℃、30分)を行った後、得られた腹膜透析液のpHを測定した。pHは、4.3であった。
100gのイコデキストリンを840mLの注射用水に溶解し、第1液を調製した。また、5.35gの塩化ナトリウム、4.48gの乳酸ナトリウム、0.257gの塩化カルシウム、および0.051gの塩化マグネシウム・六水塩を160mLの注射用水に溶解し、水酸化ナトリウムでpHを調整し、第2液を調製した。第1液840mL、第2液160mLを、実施例1と同様の条件で、充填、加熱滅菌した後、第1液、第2液および混合液(腹膜透析液)のpHを測定した。第1液のpHは4.3、第2液のpHは7.2、混合液のpHは6.2であった。
実施例1、2、および比較例1~3の腹膜透析液について、ブドウ糖の主たる分解生成物である5-ヒドロキシメチルフルフラールの指標である284nmの吸光度の経時的な変化を測定した。結果を表1及び2に示す。なお、実施例1、2、および比較例1~4の腹膜透析液の保管は60℃の恒温槽中で行い、第1液と第2液の混合(比較例2は除く)は、吸光度の測定直前に行った。
Claims (5)
- 60.0~94.0g/Lのイコデキストリンおよび0~2.34g/Lの塩化ナトリウムを含有する酸性の第1液と、アルカリ性pH調整剤を含有するアルカリ性の第2液とからなる滅菌された腹膜透析液であって、滅菌後の前記第1液のpHが5.0~5.5、滅菌後の前記第2液のpHが6.5~7.5、滅菌後に第1液と第2液を混合した後のpHが6.0~7.5である腹膜透析液。
- 前記第1液には、乳酸および乳酸塩のいずれも含まない請求項1に記載の腹膜透析液。
- 前記第2液のアルカリ性pH調整剤が、水酸化ナトリウムおよび炭酸水素ナトリウムの少なくとも一つを含む請求項1または2に記載の腹膜透析液。
- 前記第2液が、塩化ナトリウム、乳酸、乳酸ナトリウム、塩化カルシウムおよび塩化マグネシウムの少なくとも一つを含む請求項1乃至3のいずれかに記載の腹膜透析液。
- 医療用袋体に収納された請求項1乃至4のいずれかに記載の腹膜透析液であって、前記袋体は、その内部を開放可能な仕切手段によって分離されることにより形成される第1室と第2室とを有し、前記第1室は前記袋体の内外を連通する排出ポートを有するものであって、前記第1液は前記第1室に、前記第2液は前記第2室に収納されている腹膜透析液。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/435,362 US10010563B2 (en) | 2012-11-27 | 2012-11-27 | Peritoneal dialysis fluid |
EP12889157.9A EP2926835B1 (en) | 2012-11-27 | 2012-11-27 | Peritoneal dialysis fluid |
PCT/JP2012/080625 WO2014083612A1 (ja) | 2012-11-27 | 2012-11-27 | 腹膜透析液 |
JP2014549665A JPWO2014083612A1 (ja) | 2012-11-27 | 2012-11-27 | 腹膜透析液 |
CN201280075778.8A CN104619348B (zh) | 2012-11-27 | 2012-11-27 | 腹膜透析液 |
EP18163628.3A EP3372246B1 (en) | 2012-11-27 | 2012-11-27 | Peritoneal dialysis fluid |
US16/018,582 US11617764B2 (en) | 2012-11-27 | 2018-06-26 | Peritoneal dialysis fluid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2012/080625 WO2014083612A1 (ja) | 2012-11-27 | 2012-11-27 | 腹膜透析液 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/435,362 A-371-Of-International US10010563B2 (en) | 2012-11-27 | 2012-11-27 | Peritoneal dialysis fluid |
US16/018,582 Division US11617764B2 (en) | 2012-11-27 | 2018-06-26 | Peritoneal dialysis fluid |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014083612A1 true WO2014083612A1 (ja) | 2014-06-05 |
Family
ID=50827288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/080625 WO2014083612A1 (ja) | 2012-11-27 | 2012-11-27 | 腹膜透析液 |
Country Status (5)
Country | Link |
---|---|
US (2) | US10010563B2 (ja) |
EP (2) | EP2926835B1 (ja) |
JP (1) | JPWO2014083612A1 (ja) |
CN (1) | CN104619348B (ja) |
WO (1) | WO2014083612A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016175848A (ja) * | 2015-03-19 | 2016-10-06 | テルモ株式会社 | 腹膜透析液 |
CN107427409A (zh) * | 2015-03-25 | 2017-12-01 | 泰尔茂株式会社 | 医疗用袋 |
JP2019516428A (ja) * | 2016-05-06 | 2019-06-20 | ガンブロ・ルンディア・エービーGambro Lundia Ab | 透析濃縮液 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2926836B1 (en) * | 2012-11-27 | 2018-04-25 | Terumo Kabushiki Kaisha | Peritoneal dialysis fluid |
CN104619348B (zh) * | 2012-11-27 | 2018-05-01 | 泰尔茂株式会社 | 腹膜透析液 |
US11020420B2 (en) | 2016-06-09 | 2021-06-01 | Terumo Kabushiki Kaisha | Biocompatible peritoneal dialysate |
CN106176805A (zh) * | 2016-08-24 | 2016-12-07 | 华仁药业股份有限公司 | 一种妇科手术用防粘连冲洗液及其制备方法 |
EP3603675A4 (en) * | 2017-03-31 | 2020-09-02 | Terumo Kabushiki Kaisha | SOLUTION FOR PERITONEAL DIALYSIS |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000051348A (ja) * | 1998-08-11 | 2000-02-22 | Terumo Corp | 腹膜透析液 |
JP2006513211A (ja) * | 2002-12-20 | 2006-04-20 | バクスター インターナショナル インコーポレイテッド | イコデキストリンを含有する生体適合性透析液 |
JP2007524629A (ja) * | 2003-06-24 | 2007-08-30 | アドバンスド レナル テクノロジーズ | 透析のための緩衝組成物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5827820A (en) * | 1992-04-06 | 1998-10-27 | Baxter International Inc. | Aqueous peritoneal dialysis solution |
EP1008341B1 (en) * | 1997-08-22 | 2004-06-30 | Shimizu Pharmaceutical Co., Ltd. | Glucose-containing preparation |
DE10217356B4 (de) * | 2002-04-18 | 2012-03-29 | Fresenius Medical Care Deutschland Gmbh | Lösung für die Peritonealdialyse |
NZ601027A (en) * | 2010-01-04 | 2014-08-29 | Pentec Health Inc | Nutritive compositions and methods of using same |
EP2926836B1 (en) * | 2012-11-27 | 2018-04-25 | Terumo Kabushiki Kaisha | Peritoneal dialysis fluid |
CN104619348B (zh) * | 2012-11-27 | 2018-05-01 | 泰尔茂株式会社 | 腹膜透析液 |
US11020420B2 (en) * | 2016-06-09 | 2021-06-01 | Terumo Kabushiki Kaisha | Biocompatible peritoneal dialysate |
-
2012
- 2012-11-27 CN CN201280075778.8A patent/CN104619348B/zh active Active
- 2012-11-27 WO PCT/JP2012/080625 patent/WO2014083612A1/ja active Application Filing
- 2012-11-27 JP JP2014549665A patent/JPWO2014083612A1/ja active Pending
- 2012-11-27 EP EP12889157.9A patent/EP2926835B1/en active Active
- 2012-11-27 US US14/435,362 patent/US10010563B2/en active Active
- 2012-11-27 EP EP18163628.3A patent/EP3372246B1/en active Active
-
2018
- 2018-06-26 US US16/018,582 patent/US11617764B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000051348A (ja) * | 1998-08-11 | 2000-02-22 | Terumo Corp | 腹膜透析液 |
JP2006513211A (ja) * | 2002-12-20 | 2006-04-20 | バクスター インターナショナル インコーポレイテッド | イコデキストリンを含有する生体適合性透析液 |
JP2010150281A (ja) | 2002-12-20 | 2010-07-08 | Baxter Internatl Inc | イコデキストリンを含有する生体適合性透析液 |
JP2007524629A (ja) * | 2003-06-24 | 2007-08-30 | アドバンスド レナル テクノロジーズ | 透析のための緩衝組成物 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016175848A (ja) * | 2015-03-19 | 2016-10-06 | テルモ株式会社 | 腹膜透析液 |
CN107427409A (zh) * | 2015-03-25 | 2017-12-01 | 泰尔茂株式会社 | 医疗用袋 |
EP3275417A4 (en) * | 2015-03-25 | 2018-10-24 | Terumo Kabushiki Kaisha | Medical bag |
US10806669B2 (en) | 2015-03-25 | 2020-10-20 | Terumo Kabushiki Kaisha | Medical bag |
JP2020179242A (ja) * | 2015-03-25 | 2020-11-05 | テルモ株式会社 | 医療用バッグ |
CN107427409B (zh) * | 2015-03-25 | 2021-07-06 | 泰尔茂株式会社 | 医疗用袋 |
JP7021303B2 (ja) | 2015-03-25 | 2022-02-16 | テルモ株式会社 | 医療用バッグの製造方法 |
JP2019516428A (ja) * | 2016-05-06 | 2019-06-20 | ガンブロ・ルンディア・エービーGambro Lundia Ab | 透析濃縮液 |
JP7034933B2 (ja) | 2016-05-06 | 2022-03-14 | ガンブロ・ルンディア・エービー | 透析濃縮液 |
Also Published As
Publication number | Publication date |
---|---|
EP2926835B1 (en) | 2019-03-20 |
US20180296593A1 (en) | 2018-10-18 |
US20150250819A1 (en) | 2015-09-10 |
EP3372246A1 (en) | 2018-09-12 |
EP2926835A4 (en) | 2016-05-11 |
EP3372246B1 (en) | 2021-08-11 |
JPWO2014083612A1 (ja) | 2017-01-05 |
CN104619348A (zh) | 2015-05-13 |
US10010563B2 (en) | 2018-07-03 |
US11617764B2 (en) | 2023-04-04 |
CN104619348B (zh) | 2018-05-01 |
EP2926835A1 (en) | 2015-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11617764B2 (en) | Peritoneal dialysis fluid | |
WO2003059417A1 (en) | Bicarbonate-based solutions for dialysis therapies | |
WO2014083613A1 (ja) | 腹膜透析液 | |
JP6313653B2 (ja) | 腹膜透析液 | |
CN105726565A (zh) | 一种非pvc塑料包装枸橼酸钠林格注射液及其制备工艺 | |
JP3871442B2 (ja) | 腹膜透析液 | |
JP6944932B2 (ja) | 生体適合性腹膜透析液 | |
JP6216777B2 (ja) | 腹膜透析液 | |
JP6419615B2 (ja) | 腹膜透析液 | |
CN105769902A (zh) | 一种碳酸氢钠注射液的制造工艺 | |
JP7038106B2 (ja) | 腹膜透析液 | |
JP2004154558A (ja) | ろ過型人工腎臓用補液収容複室容器 | |
JP4419904B2 (ja) | 腹膜透析液 | |
JP2004283619A (ja) | 腹膜透析液調製用溶液セット |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12889157 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012889157 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14435362 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2014549665 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |